Research - San Francisco, California, United States
Mezomax Inc. is a preclinical orthopedics focused company developing a small molecule drug using patent protected methods of solvent-free mechanochemistry to accelerate osteogenesis via a novel and safe mechanism of action, in fractures, osteoporosis, and rare bone diseases. Mezomax plans to address markets where current standards of care have associated large costs to patients and healthcare burdens, as well as side effect profiles which can be eliminated with this non-toxic NCE. Mezomax is accelerating the process to bring this drug to market as a best-in-class drug for orthopedic related indications.